keyword
MENU ▼
Read by QxMD icon Read
search

Sotiriou cancer

keyword
https://www.readbyqxmd.com/read/29902299/association-of-t-cell-receptor-repertoire-use-with-response-to-combined-trastuzumab-lapatinib-treatment-of-her2-positive-breast-cancer-secondary-analysis-of-the-neoaltto-randomized-clinical-trial
#1
Ryan L Powles, David Redmond, Christos Sotiriou, Sherene Loi, Debora Fumagalli, Paolo Nuciforo, Nadia Harbeck, Evandro de Azambuja, Severine Sarp, Serena Di Cosimo, Jens Huober, Jose Baselga, Martine Piccart-Gebhart, Olivier Elemento, Lajos Pusztai, Christos Hatzis
Importance: Dual anti-HER2 blockade increased the rate of pathologic complete response (pCR) in the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) trial, and high immune gene expression was associated with pCR in all treatment arms. So far, no marker has been identified that is specifically associated with the benefit from dual HER2 blockade. Objective: To examine if use of the T-cell β chain variable genes adds to the potential association of immune gene signatures with response to dual HER2 blockade...
June 14, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29893791/trastuzumab-versus-observation-for-her2-non-amplified-early-breast-cancer-with-circulating-tumor-cells-eortc-90091-10093-big-1-12-treat-ctc-a-randomized-phase-2-trial
#2
M Ignatiadis, S Litière, F Rothe, S Riethdorf, C Proudhon, T Fehm, K Aalders, H Forstbauer, P Fasching, E Brain, P Vuylsteke, E Guardiola, R Lorenz, K Pantel, K Tryfonidis, W Janni, M Piccart, C Sotiriou, B Rack, J-Y Pierga
Background: Trastuzumab improves the outcome of women with HER2 positive breast cancer. We aimed to assess whether trastuzumab decreases the detection rate of Circulating Tumor Cells (CTCs) in women with high risk, HER2 non-amplified, early breast cancer. Patients and Methods: The EORTC 90091-10093 BIG 1-12 Treat CTC is a phase 2 trial, conducted in 70 hospitals and 6 CTC laboratories across 5 European countries. Patients with centrally confirmed HER2 non-amplified breast cancer and ≥1 centrally confirmed CTC per 15mL of blood by CellSearch® following surgery and (neo)adjuvant chemotherapy were randomized (1:1) to 6 cycles of trastuzumab intravenously versus 18 weeks of observation...
June 11, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29883450/evaluation-of-the-detection-of-toll-like-receptors-tlrs-in-cancer-development-and-progression-in-patients-with-colorectal-cancer
#3
Ippokratis Messaritakis, Maria Stogiannitsi, Asimina Koulouridi, Maria Sfakianaki, Alexandra Voutsina, Afroditi Sotiriou, Elias Athanasakis, Evangelos Xynos, Dimitris Mavroudis, Maria Tzardi, John Souglakos
BACKGROUND: Toll-like receptors (TLRs) play essential role in innate and acquired immunity, are expressed in various cell types, and are associated with altered susceptibility to many diseases, and cancers. The aim of this study was to investigate TLR2 (-196 to-174del), TLR4 (Asp299Gly and Thr399Ile) and TLR9 (T1237C and T1486C) gene polymorphisms at risk of colorectal cancer (CRC) development and progression. METHODS: Peripheral blood was obtained from 397 patients with adjuvant (stage II/III, n = 202) and metastatic (n = 195) CRC...
2018: PloS One
https://www.readbyqxmd.com/read/29869444/short-incubation-fractional-co2-laser-assisted-photodynamic-therapy-vs-conventional-photodynamic-therapy-in-field-cancerized-skin-12-month-follow-up-results-of-a-randomized-intraindividual-comparison-study
#4
Fotini Vrani, Elena Sotiriou, Elisabeth Lazaridou, Efstratios Vakirlis, Nikolaos Sideris, Eirini Kirmanidou, Zoe Apalla, Amilios Lallas, Demetrios Ioannides
BACKGROUND: Topical methyl-aminolevulinate photodynamic therapy (MAL-PDT) with 3 hours incubation is recommended as a field directed treatment. Skin pretreatment with ablative CO2 fractional laser (AFXL) prior to MAL-PDT enhances drug penetration and could minimize incubation time. OBJECTIVES: To evaluate and compare the safety and the preventive effect in the development of new non-melanocytic skin cancers (NMSCs) of AFXL-assisted MAL-PDT with one hour incubation with that of conventional MAL-PDT in patients with clinical and histological signs of field cancerization...
June 4, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29788230/tumor-infiltrating-lymphocytes-in-patients-receiving-trastuzumab-pertuzumab-based-chemotherapy-a-tryphaena-substudy
#5
Michail Ignatiadis, Gert Van den Eynden, Salgado Roberto, Marco Fornili, Yacine Bareche, Christine Desmedt, Françoise Rothé, Marion Maetens, David Venet, Esther Holgado, Virginia McNally, Astrid Kiermaier, Heidi M Savage, Timothy R Wilson, Javier Cortes, Andreas Schneeweiss, Karen Willard-Gallo, Elia Biganzoli, Christos Sotiriou
Background: There is an urgent requirement to identify biomarkers to tailor treatment in human epidermal growth factor receptor 2 (HER2)-amplified early breast cancer treated with trastuzumab/pertuzumab-based chemotherapy. Methods: Among the 225 patients randomly assigned to trastuzumab/pertuzumab concurrently or sequentially with an anthracycline-containing regimen or concurrently with an anthracycline-free regimen in the Tryphaena trial, we determined the percentage of tumor-infiltrating lymphocytes (TILs) at baseline in 213 patients, of which 126 demonstrated a pathological complete response (pCR; ypT0/is ypN0), with 28 demonstrating event-free survival (EFS) events...
May 18, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29718396/potential-benefit-of-intra-operative-administration-of-ketorolac-on-breast-cancer-recurrence-according-to-the-patient-s-body-mass-index
#6
Christine Desmedt, Romano Demicheli, Marco Fornili, Imane Bachir, Mariana Duca, Giulia Viglietti, Martine Berlière, Martine Piccart, Christos Sotiriou, Maurice Sosnowski, Patrice Forget, Elia Biganzoli
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are currently used in some countries as analgesics in primary cancer surgery. Retrospective studies suggest that NSAIDs could reduce breast cancer recurrences. Because NSAIDs also act on biological mechanisms present in patients with increased adiposity, we aimed at assessing whether the intra-operative administration of ketorolac or diclofenac would be associated with a reduction of recurrence in patients with elevated body mass index (BMI)...
April 30, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29707145/circulating-tumor-dna-in-early-response-assessment-and-monitoring-of-advanced-colorectal-cancer-treated-with-a-multi-kinase-inhibitor
#7
Caroline Vandeputte, Pashalina Kehagias, Hakim El Housni, Lieveke Ameye, Jean-François Laes, Christine Desmedt, Christos Sotiriou, Amélie Deleporte, Francesco Puleo, Karen Geboes, Thierry Delaunoit, Gauthier Demolin, Marc Peeters, Lionel D'Hondt, Jos Janssens, Javier Carrasco, Raphaël Marechal, Maria Gomez Galdon, Pierre Heimann, Marianne Paesmans, Patrick Flamen, Alain Hendlisz
Predictive biomarkers are eagerly awaited in advanced colorectal cancer (aCRC). Targeted sequencing performed on tumor and baseline plasma samples in 20 patients with aCRC treated with regorafenib identified 89 tumor-specific mutations of which ≥50% are also present in baseline plasma. Droplet digital PCR (ddPCR) assays were optimized to monitor circulating tumor DNA (ctDNA) levels in plasmatic samples collected throughout the treatment course and showed the importance of using the absolute value for ctDNA rather than the mutant/wild type ratio in monitoring the therapy outcome...
April 3, 2018: Oncotarget
https://www.readbyqxmd.com/read/29701763/pik3ca-mutations-are-associated-with-reduced-pathological-complete-response-rates-in-primary-her2-positive-breast-cancer-pooled-analysis-of-967-patients-from-five-prospective-trials-investigating-lapatinib-and-trastuzumab
#8
S Loibl, I Majewski, V Guarneri, V Nekljudova, E Holmes, E Bria, C Denkert, C Schem, C Sotiriou, S Loi, M Untch, P Conte, R Bernards, M Piccart, G von Minckwitz, J Baselga
No abstract text is available yet for this article.
April 26, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29662649/-18-fdg-pet-ct-and-molecular-markers-to-predict-response-to-neoadjuvant-chemotherapy-and-outcome-in-her2-negative-advanced-luminal-breast-cancers-patients
#9
Patricia de Cremoux, Lucie Biard, Brigitte Poirot, Philippe Bertheau, Luis Teixeira, Jacqueline Lehmann-Che, Fatiha A Bouhidel, Pascal Merlet, Marc Espié, Matthieu Resche-Rigon, Christos Sotiriou, David Groheux
Background: The efficacy of neoadjuvant chemotherapy regimens in advanced luminal breast cancer patients is difficult to predict. Intrinsic properties of breast tumors, including altered gene expression profile and dynamic evaluation of metabolic properties of tumor cells using positron emission tomography/computed tomography (PET/CT) of tumor cells, have been identified to guide patient's prognosis. The aim of this study is to determine if both analyses may improve the prediction of response to neoadjuvant chemotherapy in ER-positive / HER2-negative breast cancers (BCs) patients...
March 27, 2018: Oncotarget
https://www.readbyqxmd.com/read/29616304/tumor-metabolism-assessed-by-fdg-pet-ct-and-tumor-proliferation-assessed-by-genomic-grade-index-to-predict-response-to-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer
#10
David Groheux, L Biard, J Lehmann-Che, L Teixeira, F A Bouhidel, B Poirot, P Bertheau, P Merlet, M Espié, M Resche-Rigon, C Sotiriou, P de Cremoux
PURPOSE: Survival is increased when pathological complete response (pCR) is reached after neoadjuvant chemotherapy (NAC), especially in triple-negative breast cancer (TNBC) patients. Positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) and the genomic grade index (GGI), each separately, showed good potential to predict pCR. Our study was designed to evaluate the predictive value for the therapeutic response of a combination of parameters based on FDG-PET, histoclinical features and molecular markers of proliferation...
April 4, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29471435/immune-infiltration-in-invasive-lobular-breast-cancer
#11
Christine Desmedt, Roberto Salgado, Marco Fornili, Giancarlo Pruneri, Gert Van den Eynden, Gabriele Zoppoli, Françoise Rothé, Laurence Buisseret, Soizic Garaud, Karen Willard-Gallo, David Brown, Yacine Bareche, Ghizlane Rouas, Christine Galant, François Bertucci, Sherene Loi, Giuseppe Viale, Angelo Di Leo, Andrew R Green, Ian O Ellis, Emad A Rakha, Denis Larsimont, Elia Biganzoli, Christos Sotiriou
Background: Invasive lobular breast cancer (ILC) is the second most common histological subtype of breast cancer after invasive ductal cancer (IDC). Here, we aimed at evaluating the prevalence, levels, and composition of tumor-infiltrating lymphocytes (TILs) and their association with clinico-pathological and outcome variables in ILC, and to compare them with IDC. Methods: We considered two patient series with TIL data: a multicentric retrospective series (n = 614) and the BIG 02-98 study (n = 149 ILC and 807 IDC)...
February 20, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29470143/tumor-pik3ca-genotype-and-prognosis-in-early-stage-breast-cancer-a-pooled-analysis-of-individual-patient-data
#12
Dimitrios Zardavas, Luc Te Marvelde, Roger L Milne, Debora Fumagalli, George Fountzilas, Vassiliki Kotoula, Evangelia Razis, George Papaxoinis, Heikki Joensuu, Mary Ellen Moynahan, Bryan T Hennessy, Ivan Bieche, Lao H Saal, Olle Stal, Barry Iacopetta, Jeanette Dupont Jensen, Sandra O'Toole, Elena Lopez-Knowles, Mattia Barbaraeschi, Shinzaburo Noguchi, Hatem A Azim, Enrique Lerma, Thomas Bachelot, Qing Wang, Gizeh Perez-Tenorio, Cornelis J H Can de Velde, Daniel W Rea, Vicky Sabine, John M S Bartlett, Christos Sotiriou, Stefan Michiels, Sherene Loi
Purpose Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA) mutations are frequently observed in primary breast cancer. We evaluated their prognostic relevance by performing a pooled analysis of individual patient data. Patients and Methods Associations between PIK3CA status and clinicopathologic characteristics were tested by applying Cox regression models adjusted for age, tumor size, nodes, grade, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, treatment, and study...
April 1, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29436103/genomic-hotspots-but-few-recurrent-fusion-genes-in-breast-cancer
#13
Danai Fimereli, Debora Fumagalli, David Brown, David Gacquer, Françoise Rothé, Roberto Salgado, Denis Larsimont, Christos Sotiriou, Vincent Detours
The advent of next generation sequencing technologies has boosted the interest in exploring the role of fusion genes in the development and progression of solid tumors. In breast cancer, most of the detected gene fusions seem to be "passenger" events while the presence of recurrent and driver fusions is still under study. We performed RNA sequencing in 55 well-characterized breast cancer samples and 10 adjacent normal breast tissues, complemented by an analysis of SNP array data. We explored the presence of fusion genes and defined their association with breast cancer subtypes, clinical-pathologic characteristics and copy number aberrations...
February 13, 2018: Genes, Chromosomes & Cancer
https://www.readbyqxmd.com/read/29428479/immuno-oncology-101-overview-of-major-concepts-and-translational-perspectives
#14
REVIEW
B Allard, S Aspeslagh, S Garaud, F A Dupont, C Solinas, M Kok, B Routy, C Sotiriou, J Stagg, L Buisseret
Cancer immunotherapy is demonstrating impressive clinical benefit in different malignancies and clinical oncologists are increasingly turning their attention to immune-oncology. It is now well recognized that innate and adaptive immune cells infiltrating tumors are associated with clinical outcomes and responses to treatments, and can be harnessed to patients' benefit. Considerable advances have also been made in understanding how cancers escape from immune attack. Targeting of immunological escape processes regulated by the expression of immune checkpoint receptors and ligands and the down-modulation of tumor antigen presentation is the basis of immuno-oncology treatments...
February 8, 2018: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/29365031/unravelling-triple-negative-breast-cancer-molecular-heterogeneity-using-an-integrative-multiomic-analysis
#15
Y Bareche, D Venet, M Ignatiadis, P Aftimos, M Piccart, F Rothe, C Sotiriou
Background: Recent efforts of genome-wide gene expression profiling analyses have improved our understanding of the biological complexity and diversity of triple-negative breast cancers (TNBCs) reporting, at least six different molecular subtypes of TNBC namely Basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL) and luminal androgen receptor (LAR). However, little is known regarding the potential driving molecular events within each subtype, their difference in survival and response to therapy...
April 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29314288/the-limitations-of-dermoscopy-false-positive-and-false-negative-tumours
#16
REVIEW
V Papageorgiou, Z Apalla, E Sotiriou, C Papageorgiou, E Lazaridou, S Vakirlis, D Ioannides, A Lallas
Dermoscopy has been documented to increase the diagnostic accuracy of clinicians evaluating skin tumours, improving their ability to detect skin cancer and better recognize benign moles. However, dermoscopically 'false-positive' and 'false-negative' tumours do exist. False-positive diagnosis usually leads to unnecessary excisions. False-negative diagnosis is much more dangerous, as it might result in overlooking a cancer, with severe undesirable consequences for the patient and the physician. Therefore, management strategies should mainly focus on addressing the risk of dermoscopically false-negative tumours...
January 5, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29278737/network-science-in-clinical-trials-a-patient-centered-approach
#17
REVIEW
Venkata S K Manem, Roberto Salgado, Philippe Aftimos, Christos Sotiriou, Benjamin Haibe-Kains
There has been a paradigm shift in translational oncology with the advent of novel molecular diagnostic tools in the clinic. However, several challenges are associated with the integration of these sophisticated tools into clinical oncology and daily practice. High-throughput profiling at the DNA, RNA and protein levels (omics) generate a massive amount of data. The analysis and interpretation of these is non-trivial but will allow a more thorough understanding of cancer. Linear modelling of the data as it is often used today is likely to limit our understanding of cancer as a complex disease, and at times under-performs to capture a phenotype of interest...
December 24, 2017: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/29207087/p-stat3-in-luminal-breast-cancer-integrated-rna-protein-pooled-analysis-and-results-from-the-big-2-98-phase-iii-trial
#18
Amir Sonnenblick, Roberto Salgado, Sylvain Brohée, Tamar Zahavi, Tamar Peretz, Gert Van den Eynden, Ghizlane Rouas, Asher Salmon, Prudence A Francis, Angelo Di Leo, John P A Crown, Giuseppe Viale, Laura Daly, Bahar Javdan, Sho Fujisawa, Evandro De Azambuja, Ameye Lieveke, Martine J Piccart, Jacqueline F Bromberg, Christos Sotiriou
In the present study, in order to investigate the role of signal transducer and activator of transcription 3 (STAT3) in estrogen receptor (ER)-positive breast cancer prognosis, we evaluated the phosphorylated STAT3 (p-STAT3) status and investigated its effect on the outcome in a pooled analysis and in a large prospective adjuvant trial. By using the TCGA repository, we developed gene signatures that reflected the level of p-STAT3. Using pooled analysis of the expression data from luminal breast cancer patients, we assessed the effects of the p-STAT3 expression signature on prognosis...
February 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29177149/basal-cell-carcinoma-in-a-childhood-cancer-survivor-what-neurosurgeons-should-avoid
#19
Zoe Apalla, Eleni Sotiriou, Aimilios Lallas, Elizabeth Lazaridou, Efstratios Vakirlis, Demetrios Ioannides
Among childhood cancer survivors (CCSs), non-melanoma skin cancer (NMSC) is the most common type of second malignancy. Morbidity related to the development of NMSC in this group of patients may be sometimes unpredictable and difficult to manage. We present the case of a 49-year-old female who was a CCS and developed giant superficial basal cell carcinomas (sBCCs) over the previously irradiated field of the scalp. BCC involved the atrophic skin overlying the catheter of the peritoneal cerebral shunt that was set there for the management of hydrocephalus...
October 2017: Skin Appendage Disorders
https://www.readbyqxmd.com/read/29145561/clinical-significance-of-cd73-in-triple-negative-breast-cancer-multiplex-analysis-of-a-phase-iii-clinical-trial
#20
L Buisseret, S Pommey, B Allard, S Garaud, M Bergeron, I Cousineau, L Ameye, Y Bareche, M Paesmans, J P A Crown, A Di Leo, S Loi, M Piccart-Gebhart, K Willard-Gallo, C Sotiriou, J Stagg
Background: CD73 is an ecto-enzyme that promotes tumor immune escape through the production of immunosuppressive extracellular adenosine in the tumor microenvironment. Several CD73 inhibitors and adenosine receptor antagonists are being evaluated in phase I clinical trials. Patients and methods: Full-face sections from formalin-fixed paraffin-embedded primary breast tumors from 122 samples of triple-negative breast cancer (TNBC) from the BIG 02-98 adjuvant phase III clinical trial were included in our analysis...
April 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
75542
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"